Recombinant Human Insig2 protein is a Human Full Length protein, in the 1 to 225 aa range, expressed in Cell free, with >85%, suitable for SDS-PAGE.
대체 명칭 보기
Insulin-induced gene 2 protein, INSIG-2, INSIG2
- SDS-PAGE
Supplier Data
SDS-PAGE - Recombinant Human Insig2 protein (AB289767)
SDS-PAGE analysis of ab289767
보완 제품
Cell Lines & Lysates
AB260861
Human MFN2 (Mitofusin 2) knockout HEK-293 cell line
Advanced Validation
- 0
- 0
Reactivity 정보
서열 정보
특성 및 보관 정보
제형
배송 시 보관 조건
적절한 단기 보관 기간
적절한 단기 보관 조건
적절한 장기 보관 조건
분주 정보
보관 정보
추가 정보
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The Insig2 protein serves as an integral component in the regulation of lipid homeostasis. It participates in a protein complex including sterol regulatory element-binding proteins (SREBPs) and SCAP acting as an anchor to retain the SREBP-SCAP complex in the endoplasmic reticulum. By stopping the complex from being transported to the Golgi Insig2 prevents the activation of SREBPs which reduces cholesterol synthesis in cells. Insig2's role in maintaining lipid levels is significant in balancing energy metabolism.
Pathways
Insig2 is directly involved in the cholesterol biosynthesis pathway and the fatty acid metabolism pathway. In these pathways Insig2 works alongside proteins such as SCAP and SREBPs halting SREBPs' transport and activation when cellular sterol levels are high. This regulation plays a critical role in ensuring lipid levels remain in balance emphasizing Insig2's importance in the response to sterol changes within the cell.
일반 정보
기능
Oxysterol-binding protein that mediates feedback control of cholesterol synthesis by controlling both endoplasmic reticulum to Golgi transport of SCAP and degradation of HMGCR (PubMed : 12242332, PubMed : 16606821, PubMed : 32322062). Acts as a negative regulator of cholesterol biosynthesis by mediating the retention of the SCAP-SREBP complex in the endoplasmic reticulum, thereby blocking the processing of sterol regulatory element-binding proteins (SREBPs) SREBF1/SREBP1 and SREBF2/SREBP2 (PubMed : 32322062). Binds oxysterol, including 22-hydroxycholesterol, 24-hydroxycholesterol, 25-hydroxycholesterol and 27-hydroxycholesterol, regulating interaction with SCAP and retention of the SCAP-SREBP complex in the endoplasmic reticulum (PubMed : 17428920, PubMed : 26160948, PubMed : 32322062). In presence of oxysterol, interacts with SCAP, retaining the SCAP-SREBP complex in the endoplasmic reticulum, thereby preventing SCAP from escorting SREBF1/SREBP1 and SREBF2/SREBP2 to the Golgi (PubMed : 32322062). Sterol deprivation or phosphorylation by PCK1 reduce oxysterol-binding, disrupting the interaction between INSIG2 and SCAP, thereby promoting Golgi transport of the SCAP-SREBP complex, followed by processing and nuclear translocation of SREBF1/SREBP1 and SREBF2/SREBP2 (PubMed : 32322062). Also regulates cholesterol synthesis by regulating degradation of HMGCR : initiates the sterol-mediated ubiquitin-mediated endoplasmic reticulum-associated degradation (ERAD) of HMGCR via recruitment of the reductase to the ubiquitin ligase RNF139 (PubMed : 16606821, PubMed : 22143767).
서열 유사성
Belongs to the INSIG family.
Post-translational modifications
Phosphorylation at Ser-151 by PCK1 reduces binding to oxysterol, disrupting the interaction between INSIG2 and SCAP, thereby promoting nuclear translocation of SREBP proteins (SREBF1/SREBP1 or SREBF2/SREBP2) and subsequent transcription of downstream lipogenesis-related genes.. Polyubiquitinated by AMFR/gp78 at Cys-215 in some tissues such as adipose tissues, undifferentiated myoblasts and liver, leading to its degradation (PubMed:31953408). In differentiated myotubes, Cys-215 oxidation prevents ubiquitination at the same site, resulting in protein stabilization (PubMed:31953408).. Oxidized at Cys-215 in differentiated myotubes, preventing ubiquitination at the same site, and resulting in protein stabilization.
타겟 정보
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com